Investing.com - Hologic (NASDAQ: HOLX) reported second quarter EPS of $1.06, $0.18 better than the analyst estimate of $0.88. Revenue for the quarter came in at $1.03B versus the consensus estimate of $956.45M.
Guidance
Hologic sees Q3 2023 EPS of $0.83-$0.93 versus the analyst consensus of $0.88.
Hologic sees Q3 2023 revenue of $930.00M-$980.00M versus the analyst consensus of $959.50M.
Hologic sees FY 2023 EPS of $3.75-$3.95 versus the analyst consensus of $3.75.
Hologic sees FY 2023 revenue of $3.93B-$4.03B versus the analyst consensus of $3.97B.
Hologic's stock price closed at $87.67. It is up 5.91% in the last 3 months and up 20.24% in the last 12 months.
Hologic saw 12 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Hologic's stock price’s past reactions to earnings here.
According to InvestingPro, Hologic's Financial Health score is "great performance".
Check out Hologic's recent earnings performance, and Hologic's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar